Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | TDO2 | P48775 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27175927 | 0.89 | CES2 (0.48) | CES2CES1EPHX1 | |
| SCHEMBL182749 | 0.80 | CES2 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL182750 | 0.80 | CES2 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7473641 | 0.80 | MEN1 (0.49) | CES2CES1EPHX1SMN1; SMN2 | |
| SCHEMBL2119 | 0.80 | CES2 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10970686 | 0.80 | ESR1 (0.43) | ALDH1A1CES2CES1LMNANPC1 | |
| SCHEMBL306474 | 0.79 | HDAC3 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7680152 | 0.78 | CES2 (0.44) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL330957 | 0.78 | HDAC3 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8763327 | 0.78 | ALOX5 (0.48) | ALDH1A1CES2CES1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958861-B2 | Spirocyclic lactams as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2024-04-16 | — | — | US | disclosed |
| CN-117447514-A | Interface modification material, preparation method and application thereof in solar cell | 南昌大学 | 2024-01-26 | — | — | CN | disclosed |
| EP-4298099-A1 | SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS | Incyte Corporation (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20220281887-A1 | SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-09-08 | — | — | US | disclosed |
| WO-2022182839-A1 | SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2022-09-01 | — | — | WO | disclosed |
| EP-2588457-B1 | PYRAZOLOQUINOLINE DERIVATIVES AS DNA-PK INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8802712-B2 | Pyrazoloquinolines | MERCK PATENT GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-8802712-B2 | Pyrazoloquinolines | MERCK PATENT GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-20130150359-A1 | PYRAZOLOQUINOLINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150359-A1 | PYRAZOLOQUINOLINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150359-A1 | PYRAZOLOQUINOLINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-13 | — | — | US | disclosed |
| EP-2588457-A1 | PYRAZOLO-QUINOLINES | Merck Patent GmbH (DE) | 2013-05-08 | — | — | EP | disclosed |
| CN-103080092-A | Pyrazolo-quinolines | MERCK PATENT GMBH | 2013-05-01 | — | — | CN | disclosed |
| WO-2012000632-A1 | PYRAZOLO-QUINOLINES | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| EP-1077701-A4 | ANTI-VIRAL COMPOUNDS | LILLY CO ELI (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6358971-B1 | FOR INHIBITING THE GROWTH OF A PICORNAVIRUS | ELI LILLY AND COMPANY | 2002-03-19 | — | — | US | disclosed |
| CN-1292697-A | Anti-viral compound | LILLY CO ELI (US) | 2001-04-25 | — | — | CN | disclosed |
| EP-1077701-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958861-B2 | Spirocyclic lactams as JAK2 V617F inhibitors | JAK2, JAK1, STAT5A | HDAC3 2026/4885HDAC4 1708/4885HDAC1 1167/4885 |
| US-20130150359-A1 | PYRAZOLOQUINOLINES | PLK1, PKN3, PKN1 | HDAC3 1646/4885HDAC4 2484/4885HDAC1 1286/4885 |
| US-20220281887-A1 | SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS | JAK2, JAK1, STAT5A | HDAC3 2026/4885HDAC4 1708/4885HDAC1 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.